Genetic Diseases, Inborn  >>  Berinert (C1 esterase inhibitor (human) IV)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Berinert (C1 esterase inhibitor (human) IV) / CSL Behring
NCT00292981 / 2005-002897-31: C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

Completed
3
57
US, Canada
C1 Esterase Inhibitor, Berinert P
CSL Behring
Hereditary Angioedema
02/10
05/10
PASSION, NCT00748202 / 2008-000654-12: Berinert P Study of Subcutaneous Versus Intravenous Administration

Completed
3
24
Europe
C1-Esterase Inhibitor, Berinert P
Johann Wolfgang Goethe University Hospital, Clinical trial center Rhine-Main, ZKI Kindergerinnungslabor, Institut für Medizinische Virologie JWG-University hospital, CSL Behring, PharmaPart, University of Milan
Hereditary Angioedema
12/10
12/10
NCT02316353 / 2014-001054-42: A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Completed
3
126
Canada, US, Europe, RoW
C1-esterase inhibitor
CSL Behring
Hereditary Angioedema Types I and II
09/17
09/17
NCT00168103 / 2004-001186-17: Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

Completed
2/3
126
US, Canada, Europe, RoW
C1 Esterase Inhibitor, Berinert, Berinert P, CE1145, Placebo, Physiological saline solution
CSL Behring
Hereditary Angioedema
10/07
12/07

Download Options